# Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

> **NCT07159217** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 65 (estimated)

## Conditions studied

- Biliary Tract Cancer
- Disitamab Vedotin
- Lenvatinib
- Immune Checkpoint Inhibitors

## Interventions

- **DRUG:** Disitamab Vedotin
- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab
- **DRUG:** Toripalimab
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT07159217
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-30
- **Primary completion:** 2027-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07159217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07159217, "Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07159217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*